DE69727386D1 - Geschmacksmaskierte flüssige suspensionen - Google Patents

Geschmacksmaskierte flüssige suspensionen

Info

Publication number
DE69727386D1
DE69727386D1 DE69727386T DE69727386T DE69727386D1 DE 69727386 D1 DE69727386 D1 DE 69727386D1 DE 69727386 T DE69727386 T DE 69727386T DE 69727386 T DE69727386 T DE 69727386T DE 69727386 D1 DE69727386 D1 DE 69727386D1
Authority
DE
Germany
Prior art keywords
polymer
active ingredient
pharmaceutically active
taste
masked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727386T
Other languages
English (en)
Other versions
DE69727386T2 (de
Inventor
Mario Morella
Hamilton Pitman
Grant Heinicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
FH Faulding and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd
Publication of DE69727386D1 publication Critical patent/DE69727386D1/de
Application granted granted Critical
Publication of DE69727386T2 publication Critical patent/DE69727386T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE69727386T 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen Expired - Lifetime DE69727386T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN9697A AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions
AUPN969796 1996-05-07
PCT/AU1997/000279 WO1997041839A1 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions

Publications (2)

Publication Number Publication Date
DE69727386D1 true DE69727386D1 (de) 2004-03-04
DE69727386T2 DE69727386T2 (de) 2004-11-11

Family

ID=3794010

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727386T Expired - Lifetime DE69727386T2 (de) 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen

Country Status (11)

Country Link
US (1) US6197348B1 (de)
EP (1) EP0921789B1 (de)
JP (1) JP4624498B2 (de)
AT (1) ATE258432T1 (de)
AU (1) AUPN969796A0 (de)
CA (1) CA2253811C (de)
DE (1) DE69727386T2 (de)
DK (1) DK0921789T3 (de)
ES (1) ES2215223T3 (de)
PT (1) PT921789E (de)
WO (1) WO1997041839A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
DE19809719A1 (de) 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
ATE424191T1 (de) * 1999-02-04 2009-03-15 Abbott Lab Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
RU2002120498A (ru) * 1999-12-28 2004-04-10 Адзиномото Ко., Инк. (Jp) Противодиабетический препарат для перорального введения
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
JP4619658B2 (ja) * 2002-03-12 2011-01-26 富山化学工業株式会社 快い味の経口懸濁液および方法
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
AU2003270778B2 (en) * 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
CA2529429C (en) * 2003-06-17 2009-10-20 Filtertek Inc. Fluid handling device and method of making same
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
CA2552064A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
EP1703898A2 (de) * 2003-12-31 2006-09-27 Alpharma, Inc. Formulierungen enthaltend ziprasidon
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
EP1732513A2 (de) * 2003-12-31 2006-12-20 Alpharma, Inc. Formulierungen von rosiglitazon
CA2577852A1 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
US7378109B2 (en) * 2004-12-23 2008-05-27 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
US20060205682A1 (en) * 2005-02-25 2006-09-14 Roberts Richard H Antibiotic and combinations of antibiotic and symptomatic relief agent formulations
JP2008540437A (ja) * 2005-05-03 2008-11-20 ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド キニーネを含有する制御放出調合剤
CN1883456B (zh) * 2005-06-20 2010-12-15 常州市第四制药厂有限公司 掩味药物颗粒及其制备方法和用途
JP2007031407A (ja) * 2005-07-29 2007-02-08 Shin Etsu Chem Co Ltd 低置換度セルロースエーテル含有コーティング用組成物及び不快な味が隠蔽されたフィルムコーティング製剤
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8986735B2 (en) * 2006-03-16 2015-03-24 Novartis Ag Solid dosage form containing a taste masked active agent
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
EP2073797A2 (de) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmazeutische zusammensetzungen
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008081774A1 (ja) * 2006-12-26 2008-07-10 Shionogi & Co., Ltd. リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
JP5644495B2 (ja) 2009-03-27 2014-12-24 東レ株式会社 被覆固形製剤
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CA2792523C (en) * 2010-03-09 2018-01-09 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2013156163A1 (en) 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
EP2919903B1 (de) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Zusammensetzungen mit einem biologischen wirkstoff und einem nicht geordneten anorganischen oxid
US11202741B2 (en) * 2015-09-30 2021-12-21 Amorepacific Corporation Self-restorable core-shell capsule
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
CN113181133A (zh) * 2021-04-25 2021-07-30 海南通用三洋药业有限公司 一种罗红霉素胶囊的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
ES2054089T3 (es) * 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
WO1991019486A1 (en) * 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5578316A (en) * 1992-06-04 1996-11-26 Smithkline Beecham Corporation Palatable pharmaceutical compositions
WO1994025006A1 (en) * 1993-04-26 1994-11-10 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids

Also Published As

Publication number Publication date
CA2253811A1 (en) 1997-11-13
ES2215223T3 (es) 2004-10-01
JP2000509399A (ja) 2000-07-25
US6197348B1 (en) 2001-03-06
EP0921789A4 (de) 2002-03-13
PT921789E (pt) 2004-06-30
DK0921789T3 (da) 2004-06-01
EP0921789A1 (de) 1999-06-16
WO1997041839A1 (en) 1997-11-13
ATE258432T1 (de) 2004-02-15
AUPN969796A0 (en) 1996-05-30
JP4624498B2 (ja) 2011-02-02
EP0921789B1 (de) 2004-01-28
DE69727386T2 (de) 2004-11-11
CA2253811C (en) 2006-10-24

Similar Documents

Publication Publication Date Title
DE69727386D1 (de) Geschmacksmaskierte flüssige suspensionen
DE69032445T2 (de) Arzneimittel mit verzögerter Freigabe
CA2089430A1 (en) Aqueous pharmaceutical suspension for pharmaceutical active
ES2174849T3 (es) Composiciones farmaceuticas con sabor agradable.
GR1002094B (en) Process for the preparation of aqueous suspension for substantially water in sowble actives
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
SE8104974L (sv) Suspension av mikrokapslad bakampicillin-syraadditionssalt for oral administration, i synnerhet pa barn
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
FR2766368B1 (fr) Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
EA199900205A1 (ru) Лекарственные формы для перорального введения, содержащие бета-лактамный антибиотик
ATE374617T1 (de) Verfahren zur herstellung eines bluddrucksenkenden mittel enthaltenden ein dipeptid als wirksames bestandteil
EP0717992A3 (de) Formulierungen von wässrige Suspensionen für pharmazeutische Verwendung
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
NO983464L (no) Buffersystemer for stabilisering av farmas°ytiske preparater
NO20022828L (no) Nye forgrenede substituerte aminoderivater av 3-amino-1-fenyl- 1H[1,2,4]triazol, fremgangsmåter for deres fremstilling, ogfarmasöytiske preparater inneholdende disse
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO20021527L (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
KR900701263A (ko) 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물
NO20031030D0 (no) Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
IS3947A (is) Amínósýru afleiður, aðferð til framleiðslu þeirraog notkunar sem lyfja
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
FR2735695B1 (fr) Compositions cosmetiques ou pharmaceutiques contenant a titre de principe actif, de la mangiferine ou ses derives
NO900812L (no) Fremgangsmaate for fremstilling av terapeutisk aktive laktamderivater.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MAYNE PHARMA INTERNATIONAL PTY LTD, MELBOURNE, AU

8328 Change in the person/name/address of the agent

Representative=s name: ADVOTEC. PATENT- UND RECHTSANWAELTE, 57234 WILNSDO